ModifiedCentenePolicy CP.MP.162

Tandem Transplant

Customize your policy alerts

Sign up for Centene Policy CP.MP.162 alerts

Get alerted when Policy CP.MP.162 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity criteria for planned sequential (tandem) autologous hematopoietic cell transplants — including tandem autologous → reduced-intensity allogeneic sequences — for specified diagnoses and patient eligibility; applies to Centene-affiliated health plans and providers requesting authorization.

Policy Summary

PayerCentene

PolicyTandem Transplant

Policy CodePolicy CP.MP.162

Change TypeMaterial clinical updates (criteria, contraindications, staging)

Effective Date

Next Review Date

Key ActionObtain prior authorization and document medical necessity that the member meets the updated diagnostic and contraindication criteria before scheduling tandem transplant services.

SourceLink

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedCentenePolicy CP.MP.162

Tandem Transplant

Customize your policy alerts

Sign up for Centene Policy CP.MP.162 alerts

Get alerted when Policy CP.MP.162 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerCentene

PolicyTandem Transplant

Policy CodePolicy CP.MP.162

Change TypeMaterial clinical updates (criteria, contraindications, staging)

Effective Date

Next Review Date

Key ActionObtain prior authorization and document medical necessity that the member meets the updated diagnostic and contraindication criteria before scheduling tandem transplant services.

SourceLink

POLICY UPDATE CHANGES

Updated Criteria I.A.2. to include ovarian germ cell tumors.

Updated neuroblastoma criteria from INSS to INRGSS/COG high-risk disease group characteristics and adjusted age-related language.

Replaced prior contraindications list with a new, consolidated contraindication list (I.B.1 through I.B.6).

6explicit transplant contraindication items (I.B.1-6)

3primary diagnoses listed for tandem autologous transplant (MM, germ cell tumors, high-risk neuroblastoma)

<=6mplanned interval defining tandem transplant

indications expandedadded ovarian germ cell tumors and updated neuroblastoma staging references

1-34+bibliography entries included

Coverage Criteria for Tandem Hematopoietic Cell Transplant

Coverage criteria overview

Policy criteria and contraindications have been updated across multiple annual reviews; specific clinical inclusion criteria reference disease-specific guideline characteristics (e.g., INRGSS for neuroblastoma) and added indications such as ovarian germ cell tumors.

General approach: Coverage determination is based on disease-specific criteria aligning with guidelines (NCCN, ASBMT, COG) and the updated contraindication list I.B.1–I.B.6.

Policy updates in chunks 18 and 19 reflect these changes

Initial tandem autologous transplant

Covered when ALL of the following are met

Overall

Diagnoses: Member has one of: newly diagnosed or responsive multiple myeloma (MM); germ cell tumors refractory to cisplatin-based chemotherapy (including relapsed testicular or relapsed ovarian germ cell tumors); high-risk neuroblastoma in a member <18 years as defined by INRGSS/COG high-risk features
See detailed neuroblastoma criteria
Organ function and comorbidities: Member does not have significant dysfunction of a major organ system and/or severe comorbidities, including but not limited to: bilirubin > 2 mg/dL; INR > 1.6 (unless on oral anticoagulants); EF < 45%; FEV1 ≤ 50% predicted; DLCO ≤ 60% predicted; Karnofsky/Lansky < 70% or ECOG > 2
Contraindications enumerated in I.B.
Infection status: No uncontrolled or disseminated infection
I.B. includes infection-related exclusions

Timing: Second planned HCT is performed within the tandem interval (second HCT planned within six months of the first)<= 6 months

Definition of tandem transplant

Tandem autologous followed by HLA-identical sibling allogeneic transplant

Covered when ALL of the following are met

Autologous→Allogeneic (HLA-identical sibling): Untreated, newly diagnosed multiple myeloma when initial tandem autologous transplant is followed by an allogeneic transplant from an HLA-identical sibling with reduced-intensity conditioning and none of the contraindications in section I.B. are present

Medically necessary per section II

Tandem autologous followed by HLA-compatible unrelated allogeneic transplant

Autologous→Allogeneic (HLA-compatible unrelated): Tandem autologous followed by an allogeneic transplant from an HLA-compatible unrelated donor for untreated, newly diagnosed multiple myeloma will be considered on a case-by-case basis when contraindications in section I.B. are absent

Considered per section III

The policy language was revised to remove a prior general exclusion that stated "current evidence does not support tandem transplants for any other indication than what is listed above." The explicit removal of that broad IV statement clarifies that coverage determinations should rely on the specific, enumerated indications and updated criteria rather than the former blanket limitation.

A previous limiting statement that broadly asserted insufficient evidence for tandem transplants outside the listed indications was deleted during review. The policy now relies on the detailed, enumerated coverage criteria and contraindications rather than that earlier blanket restriction.

Tandem transplant coverage is limited to the indications explicitly listed in the criteria (for example, multiple myeloma, specified germ cell tumors including relapsed ovarian germ cell tumors, and high-risk neuroblastoma). Tandem transplants performed for other diagnoses are not supported unless those diagnoses are specifically added to the enumerated coverage criteria.

Procedures proposed for indications not encompassed by the updated listed diagnoses, or for patients who meet any of the newly consolidated contraindications (I.B.1–I.B.6), will be considered not medically necessary and may be denied under the policy.

Candidate Eligibility Criteria

Eligible candidates (oncology)

Neuroblastoma-specific eligibility

High-risk neuroblastoma criteria: Member <18 years with high-risk neuroblastoma defined by INRGSS/COG: Stage M aged ≥18 months; Stage M aged <18 months with MYCN-amplified disease; Stage MS or L2 with MYCN-amplified disease; Stage L2 with unfavorable histology aged ≥18 months; Stage M or MS aged 12–18 months with at least one unfavorable feature (unfavorable histology, segmental chromosomal aberrations, diploid tumor); Stage L1 incompletely resected tumor with MYCN amplification

Detailed list per section I.A.3 and INRGSS guidance

High-risk neuroblastoma

High-risk neuroblastoma: Member <18 years with high-risk neuroblastoma defined using INRGSS/COG high-risk disease group characteristics as specified in policy: Stage M (≥18 months), Stage M (<18 months) with MYCN amplification, Stage MS or L2 with MYCN amplification, Stage L2 with unfavorable histology ≥18 months, Stage M/MS 12–18 months with unfavorable features, or Stage L1 incompletely resected with MYCN amplification.

Neuroblastoma-specific eligibility

Contraindications and Denial Triggers

Prior Authorization

Prior Authorization Required

Prior authorization is required for tandem autologous transplants. Providers must obtain approval before scheduling the procedure to avoid claim denials.

Prior authorization required before service
Include diagnosis, planned procedure details, and treating provider information with the PA request

If any contraindication is present and documented, the request is not medically necessary and may be denied.

Denial Risk

Denial Triggers from Contraindications

Denial triggers (examples): requests will likely be denied if the record shows any contraindication above, lacks required documentation, or if treatment sequencing/therapy requirements are not met.

Member has documented contraindication (see clinical list)

Coding and Clinical Thresholds

Referenced CPT codesCPT

38205	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic.
38206	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous.
38230	Bone marrow harvesting for transplantation; allogeneic.
38232	Bone marrow harvesting for transplantation; autologous.
38240	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor.
38241	Hematopoietic progenitor cell (HPC); autologous transplantation.

Referenced HCPCS/Special codeHCPCS

S2150

Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre and post-transplant care in the global definition.

Timing window defining tandem transplant

DefinitionSecond hematopoietic cell transplant (HCT) is planned prospectively to occur within six months of the first HCT (distinct from repeat HCT for relapse).

IntentPerformed to deepen and extend response rates following initial high-dose therapy and HCT.

DocumentationPlan for a second HCT within a six-month window should be documented in the treatment plan to qualify as a tandem transplant.

Cardiac ejection fraction

ThresholdEjection fraction (MUGA or echocardiogram) < 45% is a contraindication to tandem transplant.

Assessment modalityMultigated acquisition (MUGA) scan or echocardiogram used to determine EF.

Provider Actions and Authorization Requirements

Prior Authorization

Prior authorization and medical necessity required

Prior authorization is required for tandem autologous transplant and medical necessity determinations must meet the policy criteria, including an eligible diagnosis and absence of listed contraindications.

Eligible diagnoses include MM, refractory germ cell tumors (including ovarian), and high‑risk neuroblastoma per INRGSS/COG definitions.
Absence of contraindications listed in section I.B. is required for coverage.

Prior Authorization

Obtain prior authorization before services

Obtain prior authorization consistent with the Health Plan's procedures before performing tandem transplant services; the policy framework implies PA is required.

Providers must follow the Health Plan's authorization process prior to rendering services.

Pre-Transplant Evaluation Requirements

Documentation Required

Pre‑transplant evaluation and stem cell collection

Perform standard pre‑transplant evaluation including collection/mobilization of peripheral blood stem cells (during induction recovery or after filgrastim mobilization) and assessment of organ function and performance status prior to planning tandem transplant.

Collect sufficient hematopoietic stem cells (NCCN recommends enough for two transplants when planned).
Assess organ function, pulmonary and cardiac testing, and performance status before proceeding.

Documentation Required

Disease‑specific workup, staging, and prerequisites

Ensure disease‑specific workup and staging are documented (for example, INRGSS/COG high‑risk criteria for neuroblastoma) and confirm prerequisites where applicable (e.g., CD4 > 200 cells/mm3 and effective ART when relevant as noted in policy history).

Document INRGSS‑based high‑risk neuroblastoma criteria when applicable.
When HIV history is relevant, document CD4 > 200 cells/mm3, absence of active AIDS‑defining infection, and current effective ART if required per prior policy notes.

Transplant Center and Referral Guidance

Note

Refer relapsed/refractory germ cell tumor patients to specialized centers

Refer patients with relapsed/refractory germ cell tumors to cancer centers with multidisciplinary expertise and consider high‑dose chemotherapy and autologous SCT (single or tandem) per standard practice; the policy highlights referral to specialized centers for these cases.

Patients with relapsed or platinum‑refractory germ cell tumors should be referred to a multidisciplinary cancer center and offered clinical trial participation when possible.

Note

Perform transplants at specialized, accredited centers

Perform tandem transplant procedures at appropriately accredited transplant centers with multidisciplinary transplant expertise; the policy implies care should occur in centers with relevant capabilities and referral pathways.

Policy discussion assumes standard transplant practice at specialized centers though explicit accreditation language (e.g., FACT) is not listed in the criteria window.

Post-Transplant Coverage and Follow-up

Maintenance therapy referenced (lenalidomide)

ReferencePolicy references lenalidomide maintenance following transplant in multiple myeloma trials (e.g., StaMINA) but does not define coverage for maintenance therapy in this policy.

ImplicationCoverage for maintenance therapy is not specified here and remains subject to separate coverage documents and Health Plan rules.

Provider actionIf seeking coverage for post‑transplant maintenance, submit supporting documentation and check applicable plan-level policies.

Post-transplant follow-up and supportive services

GovernancePost-transplant follow-up and supportive services are governed by the Health Plan and subject to coverage documents, state/federal requirements, and plan-level administrative policies.

Scope

Background and Rationale

A tandem transplant is defined as a prospectively planned second course of high-dose therapy with hematopoietic cell transplant performed within six months of the first. Peripheral blood hematopoietic stem cells are typically collected during recovery from induction or after filgrastim mobilization and reserved for the second preparative regimen; tandem approaches aim to deepen and prolong response in selected malignancies such as multiple myeloma and high-risk neuroblastoma.

Definitions and Staging Systems

Tandem transplant

DefinitionTandem transplant: planned second course of high‑dose therapy with HCT within six months of the first; prospectively planned rather than for relapse.

DistinctionProspectively planned tandem transplants are distinct from repeat HCT performed for disease relapse or progression.

Clinical rationaleIntended to improve depth and duration of response compared with a single transplant in selected indications.

INRGSS

DefinitionINRGSS is the International Neuroblastoma Risk Group Staging System used for neuroblastoma risk stratification (stages L1, L2, M, MS) and incorporated into the policy's high‑risk eligibility criteria.

Use in policyPolicy updated neuroblastoma criteria from INSS to INRGSS and references COG high‑risk group characteristics for eligibility.

Policy Summary

PayerCentene

PolicyTandem Transplant

Policy CodePolicy CP.MP.162

Change TypeMaterial clinical updates (criteria, contraindications, staging)

Effective Date

Next Review Date

Key ActionObtain prior authorization and document medical necessity that the member meets the updated diagnostic and contraindication criteria before scheduling tandem transplant services.

SourceLink

On This Page

Missing or incomplete documentation of organ function tests, performance status, infection status, or ART and CD4/viral load when applicable

No prior authorization on file

Planned procedure occurs before completion of required induction therapies or without documented sequencing as clinically indicated

Documentation Required

Documentation Expectations

Documentation expectations to support medical necessity and coding/billing: include comprehensive records, operative plans, and sequencing of therapies.

Clinical history and indication for tandem transplant
Results of organ function testing (hepatic panel including bilirubin, renal function/GFR, cardiac EF with MUGA or echocardiogram, pulmonary function tests FEV1 and DLCO)
Performance status (Karnofsky/Lansky or ECOG)
Infection status (cultures, imaging, TB testing) and HIV viral load/CD4 and ART status if applicable
Treatment records documenting prior induction therapies, responses, and rationale for tandem approach
Operative and perioperative plan, expected interval between sequential transplants (if applicable)

Billing Rule

Coding References for Claim Submission

Coding guidance for claim submission: report the appropriate CPT/HCPCS procedure and facility codes; include diagnosis codes that match the approved indication and any relevant modifier per payer instructions.

Include the prior authorization reference number on the claim
Use the CPT/HCPCS procedure codes that correspond to the autologous transplant and any associated procedures (facility and professional claims)
Append modifiers as required for bilateral or staged procedures per coding guidance
Submit supporting documentation on audit request to substantiate medical necessity and sequencing

Step Therapy

Treatment and Therapy Sequencing Notes

Treatment and therapy sequencing notes: tandem autologous transplant should follow appropriate induction/consolidation therapies and documented clinical response that justify a sequential transplant strategy.

Document prior systemic therapies, dates, responses (partial/complete), and rationale for tandem approach
Provide timeline showing sequencing of first and planned second transplant and intervals between procedures
If alternative therapies were contraindicated or failed, document reasons and prior attempts

ImplicationRequests may be denied if EF is below this threshold per policy contraindications.

Bilirubin

ThresholdTotal bilirubin > 2 mg/dL is a contraindication to tandem transplant.

ScopeIncluded among major organ dysfunction criteria that may result in denial if present.

ActionDocument recent laboratory bilirubin value when seeking authorization.

FEV1

ThresholdForced expiratory volume in 1 second (FEV1) ≤ 50% of predicted is a contraindication to tandem transplant.

AssessmentPulmonary function testing should document FEV1 percent predicted prior to authorization.

Denial riskRequests with FEV1 at or below this threshold may be denied per policy I.B.

DLCO

ThresholdDiffusing capacity for carbon monoxide (DLCO) ≤ 60% of predicted is a contraindication to tandem transplant.

AssessmentReport DLCO percent predicted from pulmonary function testing when requesting authorization.

ContextDLCO is listed with other pulmonary function criteria that may preclude transplant.

Performance status

ThresholdKarnofsky or Lansky score < 70% OR ECOG performance status > 2 is a contraindication to tandem transplant.

DocumentationInclude the measured performance status (Karnofsky, Lansky, or ECOG) in the medical record for authorization review.

Denial implicationMembers below these performance thresholds are at risk for denial under the policy's contraindication list.

Step Therapy

Sequencing: autologous then reduced‑intensity allogeneic

Policy references sequencing where an initial autologous HCT may be followed by a reduced‑intensity allogeneic HCT (e.g., autologous → reduced‑intensity allogeneic for untreated MM) and such sequences are covered when policy criteria and absence of contraindications are met.

Autologous followed by reduced‑intensity allogeneic transplant from an HLA‑identical sibling is medically necessary for untreated, newly diagnosed MM when I.B. contraindications are absent.

Note

Guideline‑based therapy sequencing noted (no fixed step‑algorithm)

The policy references guideline‑based sequencing of therapies (NCCN, ASBMT) and consideration of tandem approaches (including tandem autologous transplants) for selected patients, but does not mandate a specific prior‑drug or step‑therapy drug sequence in the policy text.

Tandem approaches can be considered for patients not achieving VGPR after first autologous HCT or with high‑risk features per NCCN guidance.

Billing Rule

Coding references for claims (informational)

Use the listed procedure and HCPCS codes for informational support when submitting claims: CPT codes 38205, 38206, 38230, 38232, 38240, 38241 and HCPCS S2150 are referenced in the policy.

38205, 38206, 38230, 38232, 38240, 38241
S2150

Documentation Required

Document medical necessity per policy and coverage rules

Document medical necessity in the record consistent with this clinical policy and applicable coverage documents, including documentation of diagnosis, staging (e.g., INRGSS for neuroblastoma when applicable), organ‑function assessments, and absence of contraindications.

Follow the clinical policy and applicable plan coverage documents and state/federal requirements when documenting medical necessity.

This clinical policy guides medical necessity for tandem transplant; routine post-transplant care and supportive services are covered per the member's benefit plan documents.

Provider recommendationRefer to the applicable evidence of coverage or contract for coverage details and submit necessary documentation for post-transplant services.

Clinical factorsINRGSS-based high‑risk classification incorporates stage, age, MYCN status, histology, ploidy, and segmental chromosomal aberrations.

Tandem transplant (sequential definition)

DefinitionTandem transplant describes sequential high‑dose chemotherapy with stem cell rescue — e.g., two autologous transplants or autologous followed by reduced‑intensity allogeneic transplant.

ExamplesMay include two autologous cycles of myeloablative chemotherapy with stem cell rescue given in tandem for high‑risk neuroblastoma or autologous followed by reduced‑intensity allogeneic for select MM scenarios.

FeasibilityTandem ASCT has been shown feasible in high‑risk neuroblastoma and has been evaluated in randomized trials comparing tandem versus single consolidation.

High-risk neuroblastoma

Policy inclusionHigh‑risk neuroblastoma is an indicated diagnosis for tandem transplant when defined by INRGSS/COG high‑risk disease group characteristics (e.g., Stage M ≥18 months, MYCN amplification scenarios, unfavorable histology/segmental aberrations).

EvidenceRandomized and cohort studies demonstrate improved event‑free survival with tandem ASCT in high‑risk neuroblastoma, though overall survival benefits vary by study.

Policy updatePolicy criteria were revised to adopt INRGSS/COG high‑risk definitions and to update background and coding descriptions accordingly.